Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Faster, deeper, smaller—the rise of antibody-like scaffolds

Nature Biotechnology volume 35, pages 602–603 (2017)Cite this article

Subjects

A Correction to this article was published on 09 November 2017

This article has been updated

Those are just two of the wide variety of protein scaffold drugs currently in development (Table 1). “There's a whole zoo of non-antibody scaffolds out there,” says Daniel Christ, an immunologist at the Garvan Institute of Medical Research in Sydney, Australia.

Table 1 Selected antibody-like scaffolds in development
Full size table

These tiny protein scaffolds take advantage of the high binding specificity of monoclonal antibodies—a key therapeutic modality for a range of diseases—while overcoming some of their drawbacks. In principle, the scaffolds should have considerable advantages over antibodies,” says Christ, adding that there are three major features driving the field.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 09 August 2017

    In the July 2017 issue, Janssen's fynomer drug for psoriasis was said to be discontinued “when it induced rheumatoid arthritis.” In fact, it was discontinued “after it induced transient rashes and muscle pain.” The error was corrected in the html and pdf versions of the article on 9 August 2017.

  • 13 April 2018

    In the version of this article initially published, it was stated that affibodies were invented by "a group led by Fredrik Frejd," instead of "researchers at the Royal Institute of Technology, Stockholm, and Fredrik Frejd." The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. New Brunswick, Canada

    Brian Owens

Authors
  1. Brian Owens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Owens, B. Faster, deeper, smaller—the rise of antibody-like scaffolds. Nat Biotechnol 35, 602–603 (2017). https://doi.org/10.1038/nbt0717-602

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0717-602

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing